Among them, molecular targeted therapies targeting driver genes has shown good application prospects, and the corresponding molecular targeted drugs have been developed for common lung cancer driver genes, such as epidermal growth factor receptor (EGFR), mesenchymal lymphoma kinase (ALK) and c-ros oncogene 1 receptor tyrosine kinase (ROS1), significantly prolonging progression-free survival (PFS) and overall survival (OS) outcomes for lung cancer patients (9–11). This evidence concerns the gene ROS1 and lung carcinoma.